Advertisement

Pulmonary and Systemic Inflammation

  • Ena Ray Banerjee
Chapter

Abstract

In order to begin work on a disease, with the aim to ameliorate human suffering, a researcher must first educate herself about the nitty-gritties of what is involved and what is at stake. This involves recreating the inner workings of a human disease in a nonhuman but closely related animal so as to facilitate delineation of each and every fine detail of the onset, etiology, establishment, development, progression, and exacerbations (cyclical manifestations in an exaggerated form of the disease pathology). In order to understand these inner workings, the model has to be simple enough and yet similar enough to be of any use to alleviate suffering of the human patients. The bench-to-bedside strategy therefore aims to recreate a complex disease first, part by part, outside the body (ex vivo) which enables easy dissection of nodal points of disease onset-progression, and then the entire composite disease phenotype is addressed using a whole organism by various treatments such as administration of a molecule (chemically induced), be it a drug, a polymer, an antibody or a peptide, or even an allergen or toxin, by various routes of administration, which, over various time intervals, usually manifest in a complex human disease in the subhuman primate or non-primate.

Keywords

Chronic Obstructive Pulmonary Disease Airway Hyperresponsiveness Chronic Obstructive Pulmonary Disease Exacerbation Airway Remodel Complex Human Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Udwadia ZF. The burden of undiagnosed airflow obstruction in India. J Assoc Phys India. 2007;55:547–8.Google Scholar
  2. 2.
    Yang G, Rao C, Ma J, Wang L. Validation of verbal autopsy procedures for adult deaths in China. Int J Epidemiol. 2006;35(3):741–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Murphy DM, O’Byrne PM. Recent advances in the pathophysiology of asthma. Chest. 2010;137(6):1417–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Henderson Jr WR, et~al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002;165:108–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Davidson E, Jing Jing Liub, Sheikh A. The impact of ethnicity on asthma care. Prim Care Respir J. 2010;19(3):202–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Sharm P, Halayko AJ. Emerging molecular targets for the treatment of asthma. Indian J Biochem Biophys. 2009;46(6):447–60.Google Scholar
  7. 7.
    Broide DH, Sullivan S, Gifford T, Sriramarao P. Inhibition of pulmonary eosinophilia in P selectin and ICAM deficient mouse. Am J Respir Cell Mol Biol. 1998;18(2):218–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Takizawa H. Novel strategies for the treatment of asthma. Recent Pat Inflamm Allergy Drug Discov. 2007;1:13–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Czarnobilska E, Obtułowicz K. Eosinophil in allergic and non-allergic inflammation. Przegl Lek. 2005;62(12):1484–7.PubMedGoogle Scholar
  10. 10.
    Erlandsen SL. Detection and spatial distribution of the beta 2 integrin (Mac-1) and L-selectin (LECAM-1) adherence receptors on human neutrophils by high-resolution field emission SEM. J Histochem Cytochem. 1993;41:327–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Poole PJ. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ. 2001;322:1271–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Decramer M. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT® trial. Lancet. 2005;365:1552–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Rennard SI. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Calverley PM. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.PubMedCrossRefGoogle Scholar
  15. 15.
    Holgate ST. The epithelium takes centre stage in asthma and atopic dermatitis. TRENDS Immunol. 2007;28(6):248–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Woodside DG, Vanderslice P. Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. BioDrugs. 2008;22(2):85–100.PubMedCrossRefGoogle Scholar
  17. 17.
    Cushley MJ. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol. 1983;15:161–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakajima H, Sano H, Nishimura T, Yoshida S, Iwamoto I. Role of VCAM-1/VLA-4 and ICAM-1/LFA-1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J Exp Med. 1994;179:1145–54.PubMedCrossRefGoogle Scholar
  19. 19.
    Laberge S, Rabb H, Issekutz TB, Martin JG. Role of VLA-4 and LFA-1 in allergen –induced airway hyperresponsiveness and lung inflammation in the rat. Am J Respir Crit Care Med. 1996;151:822–9.CrossRefGoogle Scholar
  20. 20.
    Schneider T, Issekutz TB, Issekutz AC. The role of α4 and β2 integrins in eosinophil and neutrophil migration to allergic lung inflammation in the BN rat. Am J Respir Cell Mol Biol. 1999;20:448–57.PubMedCrossRefGoogle Scholar
  21. 21.
    Chin JE, Hatfield CA, Winterrowd GE, Brashler JR, Vonderfecht SL, Fidler SF, Griffin RL, Kolbasa KP, Krzesicki RF, Sly LM, Staite ND, Richards IM. Airway recruitment of leukocytes in mice is dependent on alpha4-integrins and vascular cell adhesion molecule-1. Am J Physiol. 1997;272:L219–29.PubMedGoogle Scholar
  22. 22.
    Henderson Jr WR, Chi EY, Albert RK, Chu SJ, Lamm WJ, Rochon Y, Jonas M, Christie PE, Harlan JM. Blockade of CD49d (alpha4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Clin Invest. 1997;100(12):3083–92. Koo GC, Shah K, et~al. A small molecule VLA-4 antagonist can inhibit OVA –induced lung inflammation. Am J Respir Crit Care Med. 2003; 167:1400–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Larbi KY, Allen AR, Tam FW, Haskard DO, Lobb RR, Silva PM, Nourshargh S. VCAM-1 has a tissue-specific role in mediating interleukin-4-induced eosinophil accumulation in rat models: evidence for a dissociation between endothelial-cell VCAM-1 expression and a functional role in eosinophil migration. Blood. 2000;96:3601–9.PubMedGoogle Scholar
  24. 24.
    Randhawa V, Bagler G. Identification of SRC as a potent drug target for asthma, using an integrative approach of protein interactome analysis and in silico drug discovery. OMICS. 2012;16(10):513–26. Epub 2012 Jul 9.PubMedGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  • Ena Ray Banerjee
    • 1
  1. 1.Immunology & Regenerative Medicine Research UnitUniversity College of Science, Technology and AgricultureKolkataIndia

Personalised recommendations